ABACUS试验更新:肌层浸润性膀胱癌新辅助阿替利珠单抗的安全性
ABACUS试验为开放标签多中心II期研究,95例肌层浸润性膀胱癌患者接受2周期新辅助阿替利珠单抗后行根治性膀胱切除术。44%发生治疗相关不良事件,11%为3-5级,21%仅完成1周期,92%接受手术,无因毒性延迟手术,术后并发症率62%。结论认为新辅助阿替利珠单抗耐受良好,似不影响手术并发症率,但术后可能发生不良事件。
要点
- 新辅助阿替利珠单抗治疗相关不良事件发生率44%,3-5级为11%。
- 21%患者因不良事件仅接受1周期治疗,92%仍接受根治性膀胱切除术。
- 无因阿替利珠单抗毒性导致手术延迟,术后并发症率62%。
核心结论
- 2周期新辅助阿替利珠单抗耐受良好,似不影响手术并发症率。
- 因半衰期长,术后可能发生不良事件,包括需关注和干预的内分泌异常。
研究设计与样本
- ABACUS(NCT02662309)为开放标签、多中心、II期试验。
- 纳入组织学确诊的T2-T4aN0M0肌层浸润性膀胱癌等待根治性膀胱切除术患者,且不适合或拒绝顺铂为基础的新辅助化疗。
- 95例患者接受2周期新辅助阿替利珠单抗(1200 mg,每3周)后行根治性膀胱切除术。
主要发现
- 新辅助期间44%(42/95)发生阿替利珠单抗相关不良事件,常见为疲劳(20%)、食欲下降(6%)、转氨酶升高(6%)。
- 研究期间治疗相关3-5级不良事件发生率为11%(10/95)。
- 21%(20/95)因不良事件仅接受1周期阿替利珠单抗;92%(87/95)接受根治性膀胱切除术。
- 无因阿替利珠单抗相关毒性导致手术延迟。
- 手术并发症发生于62%(54/87)患者,其中43%(37/87)为轻微(1-2级),20%(17/87)为严重(3-5级)。
关键数值与推荐
- 新辅助阿替利珠单抗剂量为1200 mg,每3周,共2周期。
- 治疗相关3-5级不良事件发生率为11%(10/95)。
- 手术并发症率62%(54/87),其中严重并发症(3-5级)为20%(17/87)。
临床怎么用
- 肌层浸润性膀胱癌患者可考虑新辅助阿替利珠单抗治疗,但需监测治疗相关不良事件。
- 因半衰期长,术后应警惕迟发性免疫相关不良事件,包括肾上腺功能不全等内分泌异常。
- 新辅助阿替利珠单抗未显著延迟手术,但术后并发症率仍较高,需常规围手术期管理。
局限性
- 并非所有手术安全参数均可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: To present a comprehensive safety analysis of the largest neoadjuvant series, with focus on timing and severity of toxicity and surgical complications occurring after neoadjuvant atezolizumab in patients with MIBC enrolled in the ABACUS trial. DESIGN, SETTING, AND PARTICIPANTS: ABACUS (NCT02662309) is an open-label, multicenter, phase II trial for patients with histologically confirmed (T2-T4aN0M0) MIBC, awaiting RC. Patients either were ineligible or refused cisplatin-based neoadjuvant chemotherapy. INTERVENTION: Two cycles of neoadjuvant atezolizumab (1200 mg, every 3 wk) followed by RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Description of atezolizumab toxicity profile in the neoadjuvant setting, impact on surgery, and delayed immune-mediated adverse events (AEs) were assessed. RESULTS AND LIMITATIONS: Ninety-five patients received treatment. Of them, 44% (42/95) had atezolizumab-related AEs during the neoadjuvant period (fatigue [20%], decreased appetite [6%], and transaminases increased [6%]). Treatment-related grade 3-5 AEs occurred in 11% (10/95) of patients during the study. Of the patients, 21% (20/95) received only one cycle of atezolizumab due to AEs; 92% (87/95) underwent RC. No surgery was delayed due to atezolizumab-related toxicities. Surgical complications occurred in 62% (54/87) of patients. Of these patients, 43% (37/87) and 20% (17/87) had minor (grade 1-2) and major (grade 3-5) complications, respectively. Thirteen of 87 (15%) patients had post-RC atezolizumab-related AEs, including adrenal insufficiency and transaminases increased. Three deaths occurred during the period of study-related interventions (one non-treatment-related aspiration pneumonia, one immune-related myocardial infarction, and one cardiogenic shock after RC). Not all surgical safety parameters were available. CONCLUSIONS: Two cycles of neoadjuvant atezolizumab are well tolerated and do not seem to impact surgical complication rates. Owing to the long half-life, AEs may occur in the postoperative period, including endocrine abnormalities requiring attention and intervention. PATIENT SUMMARY: Here, we report a comprehensive dataset of patients receiving neoadjuvant immune checkpoint inhibitors before radical cystectomy. Treatment with neoadjuvant atezolizumab is safe and does not seem to complicate surgery significantly.
引用
- Szabados B, Rodriguez-Vida A, Durán I, et al. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. Eur Urol Oncol. 2021. PMID: 33612455. doi:10.1016/j.euo.2020.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。